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Background: Conventional endoscopy has low sensitivity, specificity, and interobserver agreement for the
diagnosis of gastric atrophy, intestinal metaplasia, and dysplasia. Magnification chromoendoscopy (ME) may
optimize the evaluation of premalignant gastric lesions.
Objective and Design: As part of a multicenter trial, we aimed at validating a previously proposed classification
for gastric methylene blue ME at a different center.
Setting, Patients, and Interventions: A sample of patients (nZ 42) with previously diagnosed chronic atro-
phic gastritis with or without intestinal metaplasia underwent ME (Pentax EG-3430Z) with 1% methylene blue by
2 endoscopists.
Main Outcome Measurements: A simplified version of a previously published ME classification (group I, group
II [further divided into subgroups IIE and IIF], and group III) was used for macroscopic lesions (nZ 203) with
Sydney-Houston and Vienna classifications being used for histologic analysis (n Z 479 biopsy specimens).
Results and Limitations: Excellent reproducibility (wK Z 0.92 [95% CI, 0.88-0.96]) was observed for classifi-
cation in groups and substantial reproducibility (wK Z 0.78 [95% CI, 0.72-0.84]) was found for classification in
subgroups. Global validity was 82% (range 78%-86%), showing no false negatives (sensitivity of 100% [1/1 bi-
opsy]) and a very low rate of false positives (specificity 99% [297/299 biopsies]) for dysplasia detection.
Conclusions: This classification for methylene blue ME was highly reproducible and valid for the diagnosis of
premalignant gastric lesions when used in a center different from that involved in its conception. Despite requir-
ing an unconventional endoscope and a longer procedure, these results could reinforce ME as a valuable tech-
nique in the surveillance of patients at risk for gastric cancer. (Gastrointest Endosc 2008;67:1011-8.)Gastric cancer has a high incidence worldwide and is
the second most lethal neoplasm of the digestive tract.
Moreover, in Portugal it ranks second in incidence of all
neoplastic diseases.1 Prognosis is highly dependent on
the stage at diagnosis,2 and most cases are still detected
as advanced disease with an associated poor outcome.
A well-defined cascade of premalignant conditions or
lesions has been proposed for the intestinal type of gastric
adenocarcinoma, namely, chronic gastritis, chronic atrophic
gastritis, intestinal metaplasia, and intraepithelial neoplasia
(dysplasia),3 whose identification and characterization
might help stratify individual risk. Unfortunately, in spite
Abbreviations: ME, magnification chromoendoscopy; NBI, narrow band
imaging; Pa, proportion of agreement; wK, weighted Cohen k coefficient.
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lesions, atrophy and intestinal metaplasia or even minute
dysplastic lesions present fairly inconspicuous endoscopic
features, determining a poor interobserver agreement
and low sensitivity and specificity.4-7 For this reason,
diagnosis has been based mostly on biopsy specimens
collected randomly or in predefined locations.8-11 This
might explain the widely diverging progression rates
elicited from follow-up studies,12,13 which consequently
make it harder to defend screening and monitoring.14,15
BACKGROUND
New endoscopic imaging equipment and methods
make it possible to detect subtle mucosal features not visi-
ble with conventional endoscopy, which might improve the
identification and characterization of these premalignantVolume 67, No. 7 : 2008 GASTROINTESTINAL ENDOSCOPY 1011
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a more accurate screening, evaluation of follow-up strate-
gies for high-risk groups, and, eventually, the diagnosis of
early neoplasia suitable for endoscopic resection,16,17 with
less morbidity and improved overall prognosis and survival
rates.
A previous report on methylene blue magnification
chromoendoscopy18 has shown good validity and repro-
ducibility in the diagnosis of intestinal metaplasia and
dysplasia. An external validation would be desirable to
support further evaluation of the role that this technique
may have in the secondary prevention of gastric cancer.
The aim of this study was to evaluate a classification of
premalignant gastric lesions on magnification chromoendo-
scopy with methylene blue in a new series of patients at
a different center, assessing both reproducibility and validity.
METHODS
Type of study and selection of patients
A cross-sectional study was performed that included pa-
tients with a previous diagnosis of premalignant gastric le-
sions (atrophic chronic gastritis, intestinal metaplasia)
recruited between June 2005 and September 2006 (n Z
42). Patients were excluded if they had mental disorders
or serious or debilitating renal, liver, or blood diseases
or if they had previously undergone gastric surgery.
Sixty-two percent of the patients were male; the median
age was 62 years (range 39-78 years). A subgroup of 9 pa-
tients (21%) had gastric neoplastic lesions that had previ-
ously been submitted to endoscopic resection, either by
snare polypectomy or endoscopic mucosal resection. All
patients gave informed consent, and the study was ap-
proved by the local ethics committee.
Endoscopic procedure
The endoscopic procedure was performed by 2 endo-
scopists (M.A., P.A.) at the Hospitais da Universidade de
Coimbra with use of a magnification endoscope (EG-
3430Z, Pentax Asahi Optical, Tokyo, Japan) with a variable
zoom enabling up to 105 magnification. Conscious seda-
tionwithmidazolamwas offered to 64%,whichwas decided
on a case-by-case basis (midazolam 2.6 2.4mg given intra-
venously, Mayne Pharma Portugal, Cascais, Portugal). All
examinations were performed on an outpatient basis.
After a conventional examination, 15 to 18 mL of
a mucolytic agent, 10% N-acetylcysteine (Zambon Produ-
tos Farmaceˆuticos, Lisbon, Portugal), was sprayed over
the gastric mucosa with a spray catheter (PW-5V-1, Olym-
pus Optical). Two minutes later, mucus was vigorously
washed out with a water pump (Aqua Jet HTS1500, Treier
Endoscopie, Beromu¨nster, Switzerland). Then 20 mL of
1% methylene blue (Labesfal, Campo de Besteiros, Portu-
gal) was sprayed over the mucosa and left in place for
another 2 minutes.19 After excess dye was removed by1012 GASTROINTESTINAL ENDOSCOPY Volume 67, No. 7 : 2008Capsule Summary
What is already known on this topic
d Conventional endoscopy has low sensitivity, specificity,
and interobserver agreement for the diagnosis of gastric
atrophy, intestinal metaplasia, and dysplasia.
What this study adds to our knowledge
d In a validation study performed in patients with chronic
atrophic gastritis with or without intestinal metaplasia,
magnification chromoendoscopy showed excellent
reproducibility for classification in the various groups.
d Global validity was 82%, there were no false-negative
results, and dysplasia detection had a very low rate of
false positives.
water lavage, stained and unstained mucosal areas were
magnified and biopsy specimens were taken. The median
time of the procedure was 25 minutes, with about 11 min-
utes spent on staining, 5 minutes for magnification, and
9 minutes for biopsy sampling. Patient acceptance was
moderately good, although this issue was not specifically
addressed. All examinations were fully completed and
there were no adverse events.
For the report of the chromoendoscopy patterns,
a simplified version of the classification of Dinis-Ribeiro
et al18 was used. Stained and unstained areas were magni-
fied and the following 3 groups were defined: nonmeta-
plastic, nondysplastic mucosa (I); metaplastic mucosa
(II); and dysplastic mucosa (III). It used to be that each
group had several subgroups and these were subsequently
combined for simplicity and increased interobserver
agreement20 (Fig. 1).
After a theoretic explanation of the rationale for each
group and subgroup of the classification was made,
a learning curve was accomplished by the 2 endoscopists
carrying out this study (M. A., P. A.). It consisted of a Web-
based questionnaire on a random series of endoscopic
film sequences.20
All analyzed mucosal areas (n Z 203) were digitally
recorded and classified by both endoscopists from Hospi-
tais da Universidade de Coimbra (M.A., P.A.) and again by
the author of the original classification at the Instituto
Portugueˆs de Oncologia-Porto (M.D.R.) blinded to the
results of the classification at Coimbra. Each recorded
and classified mucosal area was considered as a case for
reproducibility and validity.
Pathologic evaluation
From the 203 selected areas a total of 479 biopsy spec-
imens were taken (a mean of 2.3 and 11.4 specimens per
area and per patient, respectively). The biopsy sampling
protocol was primarily dictated by the magnification chro-
moendoscopy findings. Stained areas from the antrum,www.giejournal.org
Areia et al Magnification chromoendoscopy in premalignant gastric lesionsFigure 1. Magnification chromoendoscopy. Group I images (nonmetaplastic, nondysplastic mucosa; no color change, regular pattern): (A) round small pits,
(B) round and tubular small pits, (C) coarse round pits, (D) course round pits with a straight pit. Group II images (metaplastic mucosa; blue color change,
regular pattern): (E and F) round and tubular pits, (G and H) small pits. Group III images (dysplastic mucosa; blue color change, irregular pattern): I and J.www.giejournal.org Volume 67, No. 7 : 2008 GASTROINTESTINAL ENDOSCOPY 1013
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Magnification chromoendoscopy in premalignant gastric lesions Areia et alFigure 1 (continued)incisura, and gastric body (if present) were targeted
specifically; unstained areas were sampled from each of
the standard locations proposed by the Sydney-Houston
classification for gastritis.
Biopsy specimens were fixed in 10% buffered formalin
and embedded in paraffin wax. Histologic sections 3 mm
thick were cut and stained with hematoxylin-eosin and
giemsa.
Gastric mucosal inflammation (mononuclear cell
infiltration), activity (polymorphonuclear cell infiltra-
tion), glandular atrophy, and intestinal metaplasia were
classified in accordance with the Updated Sydney
System.21 Additional staining techniques were used to
further characterize intestinal metaplasia: alcian blue pH
2.5/periodic acidic–Schiff after diastase digestion to
categorize intestinal metaplasia as complete (type I) or
incomplete (types II and III), and high iron-diamine/alcianINTESTINAL ENDOSCOPY Volume 67, No. 7 : 2008blue pH 2.5 to identify neutral, sialomucins, and
sulfomucins.22
Chronic gastritis was defined as a chronic diffuse
inflammatory infiltrate with lymphocytes and plasmo-
cytes, expanding the lamina propria and epithelium,
with no atypical cellular nuclei. Atrophy was defined as
the disappearance of the normal glands from a certain
area of the stomach. Intestinal metaplasia was classified
as type I (nonsecreting absorptive cells and sialomucin-
secreting goblet cells), type II (few absorptive cells,
columnar cells secreting sialomucin, and goblet cells
secreting mainly sialomucin but occasionally sulfomu-
cin), and type III (columnar cells secreting predomi-
nantly sulfomucin and goblet cells secreting sialomucin
or sulphomucin).23,24
Intraepithelial neoplasia was described in 5 categories
according to the revised Vienna classification.25www.giejournal.org
Areia et al Magnification chromoendoscopy in premalignant gastric lesionsAll slides (n Z 479) were reviewed by 2 pathologists
(M.A.C. and C.M.) blinded to endoscopic results.
Statistical analysis
SPSS 13.0 (SPSS, Chicago, Ill) statistical software
package was used for data recording and analysis. To
determine the interobserver agreement, the proportion
of agreement (Pa) and weighted Cohen k coefficient
(wK) were determined (strength of agreement considered
as follows: 0.01-0.2 slight, 0.21-0.4 fair, 0.41-0.6 moderate,
0.61-0.8 substantial, and 0.81-1.0 almost perfect).26,27 For
the correspondence of the endoscopic patterns with the
histologic analysis, sensitivity, specificity, likelihood ratios,
and area under the curve values were calculated, with the
histopathologic analysis of each biopsy specimen consid-
ered the reference test.
RESULTS
Reproducibility
All stained and unstained mucosal patterns observed
could be classified according to the classification, with
no new pattern observed. For the interobserver
agreement analysis, 203 images were evaluated and
classified (Table 1).
The interobserver agreement for the classification into
groups I versus II versus III was almost perfect (wK 0.92).
If subgrouping of type II is considered (I versus IIE versus
IIF versus III), the agreement is slightly less (wK 0.78) but
still remained substantial (Table 2).
Validity
In all, 479 biopsy specimens were taken from the 203
selected mucosal areas (Table 3). Chronic atrophic gastri-
tis was diagnosed in 76% of the patients, with complete
intestinal metaplasia being present in 38%, incomplete
metaplasia in 57%, and dysplasia detected in 2% of the
cases. In those obtained from areas classified as type I,
histologic examination revealed normal mucosa, chronic
nonatrophic gastritis, or chronic atrophic gastritis without
intestinal metaplasia in 86% of cases, whereas for areas
assigned to type II the presence of intestinal metaplasia
was seen in 81%. In subtypes IIE and IIF complete intesti-
nal metaplasia was found in 24% and 13%, whereas incom-
plete intestinal metaplasia was present in 76% and 87%,
respectively (P Z .157). Of the biopsy specimens from
an area classified as type III (n Z 3), 33% exhibited
intraepithelial neoplasia.
For the diagnosis of intestinal metaplasia, the classifica-
tion had a diagnostic validity of 80%, and for the diagnosis
of intraepithelial neoplasia the diagnostic validity was 99%.
No false-negative results of intraepithelial neoplasia were
found (Table 4).www.giejournal.orgDISCUSSION
Gastric cancer of the intestinal type seems to develop
as a consequence of Helicobacter pylori infection inter-
acting with host and environmental factors.28 Progression
through a cascade of conditions or lesions leading to inva-
sive neoplasia is an infrequent and unpredictable event in
at-risk individuals. On the other hand, chronic atrophic
gastritis and intestinal metaplasia, in spite of the wide
variations of prevalence worldwide, are quite frequent
findings and their clinical relevance and management
are unsolved issues.29 Type III (sulfomucin) intestinal
metaplasia has been associated with a significantly higher
risk of progression to gastric cancer.14,30,31 However, some
authors could not reproduce these results, suggesting that
the extension of atrophy (or pseudopyloric metaplasia of
the fundic mucosa) is the most determinant factor.32,33
One of the reasons for this discrepancy might be the
inconspicuous features and the variable distribution and
extent of intestinal metaplasia. In fact, morphometric
TABLE 1. Classification in groups I, IIE, IIF, and III:
interobserver agreement analysis
Instituto Portugueˆs de
Oncologia-Porto (M. D. R.)
Classification (Hospitais da
Universidade de Coimbra)
(M. A., P. A.) I II III
I 126 120 5 1
II 76 1 74 1
III 1 0 0 1
TABLE 2. Reproducibility estimates for the Dinis-Ribeiro
et al modified classification of magnification
chromoendoscopy
Pa (95% CI) wK (95% CI)
I vs II vs III 0.96 (0.93-0.99) 0.92 (0.86-0.98)
TABLE 3. Histopathologic diagnosis according to
magnification chromoendoscopy classification
Endoscopic
classification (No.
of biopsies)
Atrophy
(No. [%])
Intestinal
metaplasia
(No. [%])
Dysplasia
(No. [%])
Group I (n Z 285) 246 (86) 39 (14) 0
Group II (n Z 165) 31 (19) 134 (81) 0
Group III (n Z 3) 0 2 (67) 1 (33)Volume 67, No. 7 : 2008 GASTROINTESTINAL ENDOSCOPY 1015
Magnification chromoendoscopy in premalignant gastric lesions Areia et alTABLE 4. Validity estimates formagnification chromoendoscopy classification in thediagnosis of intestinalmetaplasia anddysplasia
Diagnosis Se (95% CI) Sp (95% CI) LRD (95% CI) LR– (95% CI) AUC (95% CI)
Intestinal metaplasia 0.76 (0.73-0.81) 0.89 (0.86-0.92) 6.9 (4.9-156) 0.27 (0.2-0.36) 0.80 (0.77-0.84)
Dysplasia 1 0.99 (0.98-1.00) 100 (25-55532) 0 0.99 (0.99-1.00)
Se, Sensitivity; Sp, specificity; LR, likelihood ratio; AUC, area under the curve.studies have shown that intestinal metaplasia is frequently
focal, which explains the lack of sensitivity of conventional
endoscopy.34
Accurate diagnosis and quantification is crucial for
a more precise assessment of the natural history and prog-
nostic significance and the evolution after interventions
such as H pylori eradication therapy. Furthermore,
increased diagnostic accuracy and reproducibility would
allow a more comprehensive understanding of the natural
history of gastric cancer, helping to define more focused
and cost-effective screening and surveillance strategies.35
The endoscopic evaluation of gastric mucosa has been
the subject of considerable interest, and this has been re-
cently boosted by new technologic developments and the
possibility of endoscopic resection techniques. Chromo-
scopy with indigo carmine, a contrast agent that highlights
the fine morphologic features of gastric mucosa, has been
the endoscopic staining method favored, mainly for the
characterization of gastric superficial neoplasia. On the
other hand, magnification endoscopy has been used re-
cently in the detection of premalignant gastric lesions.36,37
Magnification chromoendoscopy with methylene blue,
a vital stain selectively taken up by intestinal absorptive
columnar cells, was used by Dinis-Ribeiro et al18 to evaluate
intestinal metaplasia and dysplasia. A classification was
proposed on the basis of selective staining and mucosal
pit pattern. This study yielded a good correlation to histo-
logic examination and seemed reproducible and valid; in
fact, for the diagnosis of intestinal metaplasia, sensitivity
and specificity values were 76% and 87%, respectively,
whereas for dysplasia the figures were 97% and 81%,
respectively, with a negative predictive value of 99%. More-
over, the global interobserver agreement yielded a substan-
tial k value of 0.74. However, an external validation in
a different set of patients, with different endoscopists and
even endoscopic equipment, was desirable to further
substantiate reproducibility and validity. As far as we
know, this has never been performed for other published
classifications before their use in clinical practice.
Mucosal patterns similar to those reported in the orig-
inal study were obtained, and all were classifiable into
groups I (A to D), II (E or F), or III; no new pattern was
observed. The interobserver agreement for groups I ver-
sus II versus III was nearly perfect. As for the correlation
of endoscopic patterns to histologic diagnosis, 87% of
the biopsy specimens from areas classified as type I1016 GASTROINTESTINAL ENDOSCOPY Volume 67, No. 7 : 2008revealed normal mucosa, chronic nonatrophic gastritis,
or chronic atrophic gastritis, whereas in 81% of those
from areas classified as type II intestinal metaplasia was
present, with values of sensitivity and specificity of 0.76
(0.73-0.81) and 0.89 (0.86-0.92), respectively. These results
clearly strengthen the validity and reproducibility of this
classification for the diagnosis of intestinal metaplasia.
When the subgrouping of group II into IIE and IIF is
considered, the interobserver agreement falls, mostly in
relation to subgroup IIE. Even so, global agreement
between types I versus IIE versus IIF versus III would still
be substantial.
When the diagnosis of intraepithelial neoplasia by meth-
ylene blue magnification chromoendoscopy is considered,
limitations arise from the virtual nonexistence of dysplastic
lesions in this series, probably as a result of the small num-
ber of patients, in spite of the highly selected population,
including several patients with previous superficial neopla-
sia subjected to endoscopic mucosal resection. However,
the high specificity and negative predictive values, which
are not influenced by the number of true-positive findings,
seem to indicate that this technique could be useful in the
exclusion of intraepithelial neoplasia.
As such, this magnification chromoendoscopy classifi-
cation presents a diagnostic validity of 80% and 99%,
respectively, for the detection of intestinal metaplasia
and intraepithelial neoplasia.
In the rapidly evolving field of endoscopic imaging,
new modalities are proposed and evaluated, although
they are less frequently validated and hardly ever
compared. So far, methylene blue chromoendoscopy has
provided the best results in the detection of intestinal
metaplasia. Moreover, no adverse events have been
reported. Potential DNA damage is an issue but probably
without consequence because of the short and episodic
exposure that the procedure involves.38 On the other
hand, the technique lengthens the time of the endoscopic
procedure and adds to the workload of busy endoscopic
departments. Likewise, tolerance of the procedure, even
with sedation, may be compromised. These aspects
must be taken into account when the positioning of this
modality is analyzed in the face of emerging technologies
such as narrow band imaging (NBI),39 computed virtual
chromoendoscopy,40 or confocal endomicroscopy.41 By
use of NBI with a magnifying endoscopy, Uedo et al39
recently described a distinctive endoscopic feature, a lightwww.giejournal.org
Areia et al Magnification chromoendoscopy in premalignant gastric lesionsblue crest on the epithelial surface that also seems to pro-
vide an accurate diagnosis of intestinal metaplasia. How-
ever, these promising new endoscopic techniques seem
to be limited to providing a focal diagnosis of intestinal
metaplasia. One potential advantage of methylene blue
chromoendoscopy is that it landscapes the gastric mu-
cosa, allowing an estimate of the global extent of intestinal
metaplasia, either by a subjective semiquantitative evalua-
tion, or possibly by quantitative computer image analysis.
This field assessment is probably the most relevant infor-
mation in relation to risk stratification and monitoring.
In conclusion, magnification chromoendoscopy with
methylene blue seems to be reproducible and valid for
the detection of premalignant gastric lesions, namely,
intestinal metaplasia and dysplasia, with a diagnostic valid-
ity of 80% and 99%, respectively, even at a different center.
The high specificity and negative predictive values could
justify its clinical application in the surveillance of high-
risk patients.
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